



## Clinical trial results:

### A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Primary Biliary Cholangitis Who Have an Inadequate Response or are Intolerant to UDCA

#### Summary

EudraCT number	2018-003365-34
Trial protocol	GB IT
Global end of trial date	26 September 2019

#### Results information

Result version number	v1 (current)
This version publication date	04 October 2020
First version publication date	04 October 2020

#### Trial information

##### Trial identification

Sponsor protocol code	I4V-MC-JAIV
-----------------------	-------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03742973
WHO universal trial number (UTN)	-
Other trial identifiers	Trial number: 17039

Notes:

##### Sponsors

Sponsor organisation name	Eli Lilly and Company
Sponsor organisation address	Lilly Corporate Center, Indianapolis, IN, United States, 46285
Public contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 877-CTLilly,
Scientific contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 877-285-4559,

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	26 September 2019
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	26 September 2019
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the effect of baricitinib 4-mg QD compared to placebo on PBC disease

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy:

Zero participants reported in cohort A due to protection of personal identifiable information based on enrollment futility and cohort B is not reported due to early study termination based on enrollment futility.

Evidence for comparator: -

Actual start date of recruitment	28 March 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United States: 2
Worldwide total number of subjects	2
EEA total number of subjects	0

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	2
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Zero participants reported in cohort A due to protection of personal identifiable information based on enrollment futility and cohort B is not reported due to early study termination based on enrollment futility.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Blinding implementation details:

Zero participants reported in cohort A due to protection of personal identifiable information based on enrollment futility and cohort B is not reported due to early study termination based on enrollment futility.

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Baricitinib Cohort A
------------------	----------------------

Arm description:

Participants received 2 milligram (mg) of Baricitinib tablet orally once a day for 12 weeks.

Arm type	Experimental
Investigational medicinal product name	Baricitinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received 2 milligram (mg) of Baricitinib tablet orally once a day for 12 weeks.

<b>Arm title</b>	Placebo Cohort A
------------------	------------------

Arm description:

Participants received placebo orally once daily (QD) for 12 weeks.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received placebo orally once daily (QD) for 12 weeks.

<b>Number of subjects in period 1</b>	Baricitinib Cohort A	Placebo Cohort A
Started	1	1
Completed	1	1

## Baseline characteristics

### Reporting groups

Reporting group title	Overall Study
-----------------------	---------------

Reporting group description:

Zero participants reported in cohort A due to protection of personal identifiable information based on enrollment futility.

Reporting group values	Overall Study	Total	
Number of subjects	2	2	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	0	0	
From 65-84 years	2	2	
85 years and over	0	0	
Gender categorical			
Units: Subjects			
Female	2	2	
Male	0	0	

## End points

### End points reporting groups

Reporting group title	Baricitinib Cohort A
Reporting group description:	
Participants received 2 milligram (mg) of Baricitinib tablet orally once a day for 12 weeks.	
Reporting group title	Placebo Cohort A
Reporting group description:	
Participants received placebo orally once daily (QD) for 12 weeks.	

### Primary: Change From Baseline in Alkaline Phosphatase (ALP)

End point title	Change From Baseline in Alkaline Phosphatase (ALP)
End point description:	
9999 is reported and represents no data available (NA). Zero participants reported in cohort A due to protection of personal identifiable information based on enrollment futility.	
End point type	Primary
End point timeframe:	
Baseline, Week 12.	

End point values	Baricitinib Cohort A	Placebo Cohort A		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1 <sup>[1]</sup>	1 <sup>[2]</sup>		
Units: 9999				
number (not applicable)	1	1		

Notes:

[1] - Zero participants reported in cohort A due to protection of personal identifiable information.

[2] - Zero participants reported in cohort A due to protection of personal identifiable information.

### Statistical analyses

Statistical analysis title	Statistical Analysis Cohort A
Statistical analysis description:	
Zero participants reported in cohort A due to protection of personal identifiable information.	
Comparison groups	Baricitinib Cohort A v Placebo Cohort A
Number of subjects included in analysis	2
Analysis specification	Pre-specified
Analysis type	other <sup>[3]</sup>
P-value	= 9999 <sup>[4]</sup>
Method	Other
Parameter estimate	9999

Notes:

[3] - Zero participants reported in cohort A due to protection of personal identifiable information.

[4] - Zero participants reported in cohort A due to protection of personal identifiable information.

### Secondary: Percentage of Participants With Alkaline Phosphatase (ALP) <1.67 x Upper Limit of Normal (ULN) (and at Least 15% Decrease From Baseline) and Total

## Bilirubin Level Less Than ULN

End point title	Percentage of Participants With Alkaline Phosphatase (ALP) <1.67 x Upper Limit of Normal (ULN) (and at Least 15% Decrease From Baseline) and Total Bilirubin Level Less Than
End point description: Zero participants reported in cohort A due to protection of personal identifiable information based on enrollment futility.	
End point type	Secondary
End point timeframe: Week 12	

End point values	Baricitinib Cohort A	Placebo Cohort A		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1 <sup>[5]</sup>	1 <sup>[6]</sup>		
Units: 9999				
number (not applicable)	1	1		

Notes:

[5] - Zero participants reported in cohort A due to protection of personal identifiable information.

[6] - Zero participants reported in cohort A due to protection of personal identifiable information.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Itch Numeric Rating Scale (NRS)

End point title	Change From Baseline in Itch Numeric Rating Scale (NRS)
End point description: Zero participants reported in cohort A due to protection of personal identifiable information based on enrollment futility.	
End point type	Secondary
End point timeframe: Baseline, Week 12	

End point values	Baricitinib Cohort A	Placebo Cohort A		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1 <sup>[7]</sup>	1 <sup>[8]</sup>		
Units: 9999				
number (not applicable)	1	1		

Notes:

[7] - Zero participants reported in cohort A due to protection of personal identifiable information.

[8] - Zero participants reported in cohort A due to protection of personal identifiable information.

## Statistical analyses

No statistical analyses for this end point

---

**Secondary: Change From Baseline in Fatigue NRS**

---

End point title	Change From Baseline in Fatigue NRS
-----------------	-------------------------------------

End point description:

Zero participants reported in cohort A due to protection of personal identifiable information based on enrollment futility.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12

---

End point values	Baricitinib Cohort A	Placebo Cohort A		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1 <sup>[9]</sup>	1 <sup>[10]</sup>		
Units: 9999				
number (not applicable)	1	1		

Notes:

[9] - Zero participants reported in cohort A due to protection of personal identifiable information.

[10] - Zero participants reported in cohort A due to protection of personal identifiable information.

---

**Statistical analyses**

---

No statistical analyses for this end point



## Adverse events

### Adverse events information<sup>[1]</sup>

Timeframe for reporting adverse events:

Up to 6 months

Adverse event reporting additional description:

Zero participants reported in cohort A due to protection of personal identifiable information based on enrollment futility and cohort B is not reported due to early study termination based on enrollment futility.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	18.0
--------------------	------

### Reporting groups

Reporting group title	Baricitinib Cohort A
-----------------------	----------------------

Reporting group description:

Participants received 2 mg of Baricitinib tablet orally once a day for 12 weeks.

Reporting group title	Placebo Cohort A
-----------------------	------------------

Reporting group description:

Participants received placebo orally once daily (QD) for 12 weeks.

Serious adverse events	Baricitinib Cohort A	Placebo Cohort A	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Baricitinib Cohort A	Placebo Cohort A	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: Zero participants reported in cohort A due to protection of personal identifiable information based on enrollment futility and cohort B is not reported due to early study termination based on enrollment futility.

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
28 September 2018	<p>The following changes were made to the protocol:</p> <p>Study population: A note was added on number system used for inclusion and exclusion criteria to avoid confusion to the numbering.</p> <p>Exclusion Criteria: Added clarifying language that cirrhosis should include complications.</p> <p>Method of Treatment Assignment: Changed method from stratification to dynamic minimization.</p> <p>Permanent discontinuation from study treatment: added discontinuation criterion of eFGR <math>\leq 40\text{mL/min/1.73m}^2</math>.</p> <p>Minor editorial changes for clarity were made.</p>

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Zero participants reported in cohort A due to protection of personal identifiable information based on enrollment futility and cohort B is not reported due to study termination based on enrollment futility.

Notes: